Purification and characterization of a soluble calnexin from human placenta  by Olsen, Dorthe T. et al.
Protein Expression and Puriﬁcation 92 (2013) 105–111Contents lists available at ScienceDirect
Protein Expression and Puriﬁcation
journal homepage: www.elsevier .com/ locate /yprepPuriﬁcation and characterization of a soluble calnexin from human
placenta1046-5928  2013 The Authors. Published by Elsevier Inc.
http://dx.doi.org/10.1016/j.pep.2013.09.006
⇑ Corresponding author. Fax: +45 32683149.
E-mail address: gh@ssi.dk (G. Houen).
1 Abbreviations used: Crt, calreticulin; Cnx, calnexin; ER, endoplasmic reticulum;
MHC, major histocompatibility complex; PPI, protein prolyl isomerase.
Open access under CC BY-NC-ND license.Dorthe T. Olsen a, Li Peng b, Soﬁe D. Træholt a, Karen Duus a, Peter Højrup b, Gunnar Houen a,⇑
aDepartment of Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut, Artillerivej 5, DK-2300 Copenhagen, Denmark
bDepartment of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark
a r t i c l e i n f o a b s t r a c tArticle history:
Received 28 June 2013
and in revised form 26 August 2013







ChaperoneCalreticulin (Crt) and calnexin (Cnx) are homologous endoplasmic reticulum (ER) chaperones involved in
protein folding and quality control. Crt is a soluble ER luminal Mr 46 kDa protein and Cnx is a Mr 67 kDa
ER membrane protein. During puriﬁcation of Crt from human placenta a soluble form of Cnx (sCnx) was
consistently identiﬁed in a separate ion exchange chromatography peak. The sCnx was further puriﬁed
and characterised. This showed that the protein had been cleaved after residue 472 (between Gln and
Met), thus liberating it from the transmembrane and cytoplasmic parts of Cnx. The extraction and initial
puriﬁcation steps were carried out in the presence of protease inhibitors, thus ruling out that the cleavage
was an artefact of the isolation procedure. This indicates that sCnx may have a physiological chaperone
function similar to that of Crt.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Calnexin (Cnx)1 and calreticulin (Crt) are important chaperones
in the endoplasmic reticulum (ER) and participate in the folding
and quality control of many client proteins [1–3]. The two proteins
are homologous with 45% sequence identity (based on Crt) in their
globular and P domains (Fig. 1; Suppl. Fig. 1). However, they differ
with respect to several features: Cnx is a transmembrane protein
and has a short cytoplasmic C-terminus and ER luminal N and P do-
mains, whereas Crt is a soluble ER luminal protein with a large
capacity for Ca2+ binding in the C-terminus. Despite their similar
structures and overlapping properties they seem to complement
each other in the folding of other proteins, in particular the folding
of MHC I [4–7]. Moreover, they seem to be able to substitute for each
other in many respects [8–9]. Therefore, differences in some of their
cellular functions may stem from one being a membrane protein and
the other a soluble protein. However, some differences may also be
related to the small differences in structure: Cnx has a longer P do-
main ‘‘arm’’ and Crt has a longer C-terminus (Fig. 1), otherwise their
structures in the globular domains are essentially similar.Previously, Crt has been isolated from human placenta and
characterized extensively [10–16]. Here, the isolation and charac-
terization of a soluble Cnx (sCnx) variant from human placenta is
reported.Materials and methods
Chemicals
Carbonate buffer pH 9.6 (15 mM Na2CO3, 35 mM NaHCO3,
0.001% (w/v) phenolred), TTN buffer, pH 7.5 (0.025 M Tris, 0.5%
(v/v) Tween 20, 0.15 M NaCl), alkaline phosphatase (AP) substrate
buffer, phosphate-buffered saline (PBS) (10 mM NaH2PO4/Na2-
HPO4, pH 7.3, 0.15 M NaCl) were made in-house. Pyronin G, Tween
20, NaH2PO4, Na2HPO4, NaCl, CH3COOH, Na2S2O3, CaCl2, MgCl2,
(NH4)2SO4 and dimethylformamide (DMF) were from Merck
(Darmstadt, Germany). Tris, BisTris, ammonium sulfate, para-nitro-
phenylphosphate (pNPP) substrate tablets, 5-bromo-4-chloro-3-
indolylphosphate (BCIP), nitroblue tetrazolium (NBT), phenol red,
Triton X-114, NaHCO3, Na2CO3, NH4HCO3, glycine, urea, thiourea,
guanidine (Gu) hydrochloride, triﬂuoroacetic acid (TFA), CH3CN,
glycerol, HCHO (37% (w/v), diethanolamine, AP-conjugated rabbit
immunoglobulins (Igs) against mouse IgG, AP-conjugated goat Igs
against rabbit IgG and endoprotease AspN (E.C. 3.4.24.33) were
purchased from Sigma Aldrich (St. Louis, MO, USA). HCOOH and
bovine serum albumin (BSA) were from Fluka (St. Louis, MO,
USA). Protein puriﬁcation equipment (Äkta Prime™), Q-Sepharose













Fig. 1. Comparison of calnexin and calreticulin. The red line indicates the sequence of Crt and Cnx that aligns according to the alignment in Suppl. Fig. 1 with the inserts into
the Crt sequence shown as grey bars. The location of the P-domain, the transmembrane region and the terminal Gln 472 of sCnx are indicated. Numbering is according to the
sequence including signal sequence. Numbers above the line are for Cnx and below the line for Crt.
Fig. 2. Puriﬁcation scheme for human placenta Crt. The soluble Cnx was obtained
during the Q Sepharose ion exchange chromatography (IEC).
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trypsin (porcine) (E.C. 3.4.21.4) was from Promega (Madison, WI,
USA). Triﬂuoroacetic acid (TFA) and bicinchoninic acid (BCA) pro-
tein assay kit were from Thermo Fisher Scientiﬁc (Waltham, MA,
USA). MaxiSorp™ microtitre plates were from Nunc (Roskilde,
Denmark). Complete protease inhibitor cocktail tablets were from
Roche Diagnostics (Mannheim, Germany). Rabbit antibodies recog-
nizing the N-terminus or C-terminus of Crt were produced as de-
scribed [17]. Rabbit antibodies to ERp57 were a generous gift
from Lars Ellgaard (Department of Biology, University of Copenha-
gen, Denmark). Rabbit antibodies recognizing the N-terminus or C-
terminus of Cnx were from Calbiochem (La Jolla, CA, USA). Rabbit
antibodies to ERp72 were from Abcam (Cambridge, UK). Rabbit
antibodies to PDI were from Stressgen (Victoria, British Columbia,
Canada). Precast Tris–glycine gels (4–20%) were from NOVEX (San
Diego, CA, USA). GelCode Blue Stain Reagent and bis(succinim-
idyl)suberate (BS3) were from Pierce (Rockford, IL, USA). Pre-
stained sodium dodecyl sulphate polyacrylamide gel
electrophoresis (SDS–PAGE) molecular weight standards were
from BioRad (Hercules, CA, USA). SDS and AgNO3 were from BDH
Chemicals (Poole, Dorset, UK). EtOH was from Kemetyl (Køge, Den-
mark). Poros oligo R2 microcolumns were from Applied Biosystems
(Foster City, CA, USA). Ultradiaﬁlters were fromMillipore (Billerica,
MA, USA). ReproSil Pur C18 AQ 3 um was from Dr. Maisch GMBH
(Ammerbuch-Entringen, Germany).
SDS–PAGE
SDS–PAGE was carried out according to Laemmli [18] as de-
scribed by Studier [19] using precast 4–20% gels. Samples were
boiled 1:2 with sample buffer (70 mM SDS, 100 mM dithiothreitol
(DTT), 10% (v/v) glycerol, 0.05 M Tris pH 6.8, 0.06% (w/v) pyronin
G), 15 lL was added/well and electrophoresis was carried out,
using 0.024 M Tris, 0.192 M glycine, 0.1% SDS (w/v) pH 8.8 as run-
ning buffer, at 125 mA/gel. Gels were rinsed 2  10 min in water,
stained with Coomassie Brilliant Blue (GelCode Blue) for 1 h and
then destained in water. Silver staining of gels was done as follows:
ﬁrst, gels were ﬁxed in 50% (v/v) EtOH, 12% (v/v) CH3COOH for 1 h,
then they were rinsed in 30% (v/v) EtOH for 3  20 min, treated
with 0.02% (w/v) Na2S2O3 for 1 min, rinsed in water 3  20 s,
stained with 0.02% (w/v) AgNO3, 0.03% (w/v) HCHO for 20 min,
rinsed in water 2  20 s and developed in 6% (w/v) Na2CO3,
0.4  103% (w/v) Na2S2O3, 0.02% (w/v) HCHO for 2–10 min. The
staining was stopped with 50% (v/v) EtOH, 12% (v/v) CH3COOH
for 15 min and gels ﬁnally rinsed with water.
Immunoblotting
SDS–PAGE gels were sandwiched between 12 sheets of What-
man paper no 1 equilibrated in 10 times diluted electrophoresisbuffer and subjected to electroblotting to nitrocellulose mem-
branes overnight at 0.1 mA/cm2 using a semi-dry electroblotting
apparatus (JKA Biotech, Copenhagen, Denmark). The membranes
were blocked for 1 h in 50 mM Tris, 1% (v/v) Tween 20, 0.3 M NaCl,
pH 7.5 (TTN), washed three times in TTN, and then incubated with
antibodies diluted 1:1000 in TTN. After 1 h incubation the mem-
branes were washed three times in TTN, followed by incubation
for 1 h with AP-conjugated rabbit Igs against mouse IgG or AP-con-
jugated goat Igs against rabbit IgG diluted 1:1000 in TTN. After an-
other three washes, bound antibodies were detected by incubation
with staining solution (12.5 mg 5-bromo-4-chloro-3-indolylphos-
phate in 0.5 ml DMF and 25 mg nitroblue tetrazolium in 0.5 ml
70% (v/v) DMF added to 75 ml 100 mM Tris, 100 mM NaCl, 5 mM
MgCl2, pH 9.5).
Cnx and Crt puriﬁcation
Crt was puriﬁed from human placenta as previously described
[11] with minor modiﬁcations (Fig. 2). A placenta was ﬁrst homog-
enized twice with 20 mM BisTris, 1 mM CaCl2, pH 7.5 in the pres-
ence of protease inhibitors (Complete tablets) followed by two
rounds of homogenization with 0.5 L 20 mM BisTris, 1 mM CaCl2,
pH 7.5, 1% (v/v) Triton X-114. Between homogenizations, the pre-
cipitate was separated from the supernatant by 20 min of centrifu-
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last two homogenizations were pooled and diluted with an equal
volume of 20 mM BisTris, 1 mM CaCl2, pH 7.5, 3% (v/v) Triton X-
114. Subsequent temperature-dependent phase separation was
performed by overnight incubation at 37 C. The upper phase con-
taining water-soluble proteins was isolated by aspiration and
337 g/L ammonium sulfate was added. After stirring overnight
the mixture was centrifuged 1 h at 15,000g. The supernatant was
subjected to ultradiaﬁltration through a 10 kDa cut-off ﬁlter
against 5 volumes of 20 mM Tris, 1 mM CaCl2, pH 7.5 to a ﬁnal vol-
ume of 350 ml. The retentate was applied to a Q Sepharose Fast
Flow ion exchange column equilibrated with 20 mM Tris, 1 mM
CaCl2, pH 7.5. Proteins were eluted from the column with a linearly
increasing gradient of NaCl (0–0.5 M) in 20 mM Tris, 1 mM CaCl2,
pH 7.5. (Flow rate: 1 mL/min, 6 column volumes in all). Crt-con-
taining fractions were identiﬁed by SDS–PAGE and enzyme-linked
immunosorbent assay (ELISA) using antibodies directed against
Crt’s C-terminus [17]. Similarly, Cnx-, ERp57-, ERp72- and protein
disulphide isomerase (PDI)–containing fractions were located by
SDS–PAGE and ELISA.
For some purposes, Crt was further puriﬁed by size exclusion
chromatography on a Sephacryl S-100 column (16 cm  80 cm)
equilibrated and eluted with 20 mM Tris, pH 7.5 (Flow rate:
1 mL/min).
Cnx was further separated from ERp72 by hydrophobic interac-
tion chromatography on a Phenyl-Sepharose 6 Fast Flow column
equilibrated in 50 mM sodium phosphate, 1.7 M (NH4)2SO4, pH
7.0 and eluted with a decreasing gradient of ammonium sulfate
(1.7 M) in 50 mM sodium phosphate, pH 7.0.
ELISA
Fractions were coated onto the surface of the wells of microtitre
plates (MaxiSorp), using 0.05 M sodium carbonate, pH 9.6 as coat-
ing buffer (dilution 1:50). Coating was carried out overnight at 4 C
using 100 lL/well. After coating, the plates were washed three
times for 1 min in washing buffer (TTN; 50 mM Tris, 0.15 M NaCl,
1% (w/v) BSA, 1% (v/v) Tween 20; or PBS, pH 7.3, 0.5% (v/v) Tween
20), blocked for 1 h in washing buffer, followed by 1 h incubation
at room temperature with antibodies diluted 1:1000 in incubation
buffer (the same as washing buffer). The plates were washed 3
times 1 min in washing buffer, incubated 1 h with AP-conjugated
goat Igs against rabbit IgG, or AP-conjugated rabbit Igs against
mouse IgG 1:1000 in incubation buffer, followed by three washes.
Finally, bound antibodies were quantiﬁed using p-NPP (1 mg/ml)
in AP substrate buffer (1 M diethanolamine, 0.5 mM MgCl2, pH
9.8). The absorbance was read at 405 nmwith background subtrac-
tion at 690 nm.
Mass spectrometry (MS)
Intact mass analysis
A Cnx sample was denatured by 10 mM DTT in 6 M GuHCl,
100 mM Tris buffer, pH 8.3 for 3 h at 37 C. The buffer was subse-
quently exchanged by 50% (v/v) CH3CN, 0.1% (v/v) formic acid and
injected into the nano source via a syringe pump (direct infusion)
at a ﬂow rate of 20 lL/h. The nano source was coupled to a Waters
Premier QTOF (Waters Micromass, Manchester, UK).
The mass spectrometric conditions were the following: positive
ion mode; API collision gas: on; capillary: 2.3 kv; sampling cone:
3.5; extraction cone: 2.5; ion guide: 2.9; temperature: source:
80 C; nano ﬂow: 0.2 bar.
Bottom-up analysis
Three times 5 lg Cnx was lyophilized and re-dissolved in 6 M
urea, 2 M thiourea, reduced and alkylated. The samples werediluted by 10 vol 50 mM NH4HCO3 and digested by 2% (w/w) tryp-
sin, and 2% (w/w) Asp-N overnight at 37 C separately. The peptide
mixtures were desalted using Poros Oligo R2 RP microcolumns.
The nanoLC-MS/MS was performed by a Proxeon 1100 easy-nLC
system (Thermo Fisher Scientiﬁc/Proxeon Biosystems, Odense,
Denmark). The peptides were loaded onto a 100 lm ID, 18 cm RP
capillary column (packed in house with ReproSil Pur C18 AQ
3 lm sorbent) in buffer A (0.1% (v/v) formic acid, 5% (v/v) CH3CN).
The peptides were eluted using a 50 min gradient from 0 to 34% B-
buffer (95% (v/v) CH3CN, 0.1% (v/v) formic acid) at 350 nL/min ﬂow
rate and via nanoelectrospray introduced into an LTQ-Orbitrap XL
mass spectrometer (Thermo Fisher Scientiﬁc, Bremen, Germany). A
full MS scan in the mass area of 300–1800 m/z was performed in
the Orbitrap with a resolution of 30.000 FWHM and a target value
of 110(6) ions. For each full scan the top 5 intense ions (>+1 charge
state) were selected for collision-induced dissociation (CID).
Parameters for acquiring CID were as follows: activation time,
15 ms; normalized energy, 35; Q-activation, 0.25; dynamic exclu-
sion, enable with repeat count 1; exclusion duration, 30 s.
Chemical cross-linking
50 lg Cnx interacted with 1.5 mg BS3 for 1 h and the reaction
was quenched by 100 mM NH4HCO3. The sample was reduced,
alkylated and digested by 2% (w/w) trypsin. The cross-linked pep-
tides were separated by strong cation exchange (SCX) chromatog-
raphy using a polySULFOETHYL A, 1501 mm, 5 lm particles, 300 Å
pore size column (Poly LC Inc, Columbia, MD, USA). The buffer sys-
tem was A: 0.1% (v/v) TFA, 30% (v/v) CH3CN, B: A + 0.5 M NaCl and
the gradient was: 0% B (10 min); 0–40% B (30 min); 40–90% B
(5 min); 100% B (5 min), at a ﬂow rate of 50 lL/min. The separation
was performed on an Agilent 1200 HPLC (Agilent Technologies,
Santa Clara, CA, USA). All peaks were collected and divided into 4
fractions. Each fraction was desalted using Poros Oligo R2 RP
microcolumns.
Samples were run by nano LC–MS/MS like for bottom-up anal-
ysis, except that the selected ions were selected for high energy
collision dissociation (HCD) and detected at a resolution of 7500
FWHM. The settings for the HCD were as follows: threshold for
ion selection, 15.000; target value of ions used for HCD 210(5);
activation time, 10 ms; isolation width, 2.5; normalized collision
energy, 42; repeat count, 1; repeat duration, 30; exclusion dura-
tion, 45.
Data analysis
Bottom-up analysis was performed using X!Tandem
(2010.01.01.4) through the GPMAW software version 9.21 (Light-
house Data, Odense, Denmark). Search parameters were: Parent
error 8 ppm; fragment error 0.5 Da, max. e-value 0.001; partial
modiﬁcations: oxidation of Met; ﬁxed modiﬁcations: carbami-
domethylation of Cys; semi cleavage enabled (Suppl. Fig. 3).
Identiﬁcation of cross-linked peptides was done using CrossWork
version 0.105 [20].Results
In Fig. 2, a puriﬁcation scheme used for Crt puriﬁcation is shown
and Table 1 summarizes typical results from two puriﬁcations. Ini-
tially, a human placenta was cut into small pieces and homoge-
nized in a food processor using 0.5 L 20 mM BisTris, 1 mM CaCl2,
pH 7.5 as buffer. After centrifugation, the precipitate was re-
homogenized with an equal volume of BisTris buffer. After another
centrifugation, the precipitate was homogenized in the same way
twice with 0.5 L 20 mM BisTris, 1 mM CaCl2, pH 7.5, 1% (v/v) Triton
X-114 as buffer. The combined supernatants from this detergent
Table 1
Puriﬁcation yields of Crt (A, B) and sCnx (C) from human placenta. ND: not determined. NA: not applicable.
Step Volume mL Protein (P) mga Crt, Cnx mgb,e Purity (Crt, Cnx/P) Protein A280c,f Yield (%) Puriﬁcation factor
A (Crt)
Sup. after Homog. 1650 9900 25 3 103 ND 100 1
Sup. after Precip. 2660 1596 21 13 103 ND 84 4.3
Dialysis 360 1656 13 8 103 ND 52 2.7
Q-Sepharose eluate 62 19 15 0.8–0.9 16 60 300
Diaﬁltration 12 13 12 0.9–1.0 12 48 333d
B (Crt)
Sup. after Homog. 1730 12,456 47 4 103 ND 100 1
Sup. after Precipitation 2825 2260 31 13 103 ND 66 3.3
Dialysis 340 1632 22 13 103 ND 47 3.3
Q-Sepharose eluate 54 18 20 1.0–1.1 20 42 250d
Diaﬁltration 15 17 16 0.9 17 34 225
Step Volume mL Protein (P) mga Crt mge Purity (Crt/P) Protein A280f Yield (%) Puriﬁcation factor
C (Cnx)
Sup. after Homog. 1730 12,456 155 12 103 ND 100 1
Sup. after Precipitation 2825 2260 11 5 103 ND 7 0.4
Dialysis 340 1632 26 15 103 ND 17 1.3
Q-Sepharose eluate 70 ND 3 NA ND 2 NA
Diaﬁltration 6 ND 3 NA ND 2 NA
a BCA assay.
b ELISA.
c E280 (Crt) = 2.13.
d Theoretical limit.
e SDS–PAGE scanning.
f E280 (Cnx) = 1.
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with 3% (v/v) Triton X-114 to reach a ﬁnal detergent concentration
of 2% (v/v) and incubated af 37 C to induce temperature-depen-
dent phase separation. The water phase, containing the soluble
ER proteins, was subjected to ammonium sulfate precipitation
and the supernatant from this, containing very soluble ER proteins
and some contaminating proteins was further puriﬁed.
Fig. 3 shows the resulting ion exchange chromatogram of pro-
teins from the supernatant of the ammonium sulphate precipita-
tion, when loaded on a Q-Sepharose column and eluted by a
linearly increasing salt gradient. Fractions were monitored by ELI-
SA (Fig. 3) and selected fractions analyzed by SDS–PAGE (Fig. 4).
Major bands in the SDS–PAGE gels were identiﬁed by MS and the
elution proﬁles of dominating proteins are shown in Fig. 3. Crt















Fig. 3. Chromatogram from Q-Sepharose chromatography of human placenta ER extract
relative ELISA absorbance values (absorbance value divided by maximum value for the sp
PAGE are shown by small numbers. The chromatography has been performed 10 timespeak. Interestingly, ERp57 elutes well before and completely sepa-
rated from Crt at 0.3 M NaCl. The prominent peak eluting at
0.40 M NaCl just before the Crt peak turned out to be a mixture
of ERp72 and Cnx. The presence of Cnx was unexpected, since it
is a membrane protein. However, it was reproducibly observed in
the same amount relative to Crt, approximately 3 mg Cnx and
15 mg Crt per placenta (Table 1). The yield of Crt relative to the
starting homogenate was approximately 40% and the purity was
close to 100%, a conclusion supported by SDS–PAGE and LC–MS
analysis. The yield relative to the total amount of Crt in a placenta
is not known, but from SDS–PAGE and immunoblotting analyses of
the extracts it was estimated to be approximately 20%, that is,
about half of the Crt present in a placenta is recovered in the deter-
gent extract, and about half is lost in the ﬁrst buffer extract. The
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Fig. 4. SDS–PAGE analysis of selected fractions from Fig. 3. The gel was stained with
Coomassie Brilliant Blue and the contents of the lanes are as follows: A. 1. Molecular
weight standard, 2. ER extract, 3, Fr. 20, 4. Fr. 80, 5. Fr. 83, 6. Fr. 86, 7. Fr. 91, 8. Fr.
125, 9. Fr. 132, 10. Fr. 134. B. 1. Molecular weight standard, 2. Fr. 136, 3. Fr. 138, 4.
Fr. 140, 5. Fr. 141, 6. Fr. 142, 7. Fr. 144, 8. Fr. 146, 9. Fr. 147, 10. Fr. 148.
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chromatography was approximately 60%. The major other protein
present was ERp72, identiﬁed by MS [19]. The two proteins be-
haved very similarly during chromatography, but could be sepa-
rated by hydrophobic interaction chromatography (HIC) (Fig. 5).
Characterization of the soluble Cnx by MS showed that it was














Fig. 5. Hydrophobic interaction chromatography of sCnx-containing peak from Fig. 3. Elut
analysed by SDS–PAGE are shown by small numbers. The chromatography has been perby bottom-up analysis using trypsin and Asp-N. This showed a cov-
erage of 95.6% with no modiﬁcations observed (Suppl. Fig. 3). The
intact molecular mass was measured to be 51.412 Da (theoretical
mass of Cnx 21–472 is 51.409 Da; Suppl. Fig. 2), showing that the
sCnx had an intact N-terminus starting at residue 21 and did not
contain posttranslational modiﬁcations other than disulphide
bonds. Thus, the soluble Cnx corresponds to the globular and P do-
mains of Crt (Fig 1). This explains its solubility, since the trans-
membrane part had been cleaved off together with the cytoplasmic
C-terminus by a speciﬁc but yet unknown mechanism. It should be
noted that the whole puriﬁcation starts with homogenization in
the presence of a protease inhibitor cocktail, and that the Crt elu-
tion proﬁle shows no signs of proteolytic degradation and neither
do ERp57 or ERp72 [20] (Fig. 6).
The puriﬁcation scheme (Fig. 2) was changed systematically in
several ways to investigate the inﬂuence of the different steps on
the elution proﬁle of the major proteins (i.e., omission of the
ammonium sulfate precipitation and omission of phase separation
and ammonium sulfate precipitation). However, this did not
change the order of elution of the proteins and ERp57 eluted well
separated from Crt under all conditions, with and without Ca2+
added (results not shown).
Chemical cross-linking of the soluble Cnx was carried out in
three different experiments, and positive identiﬁcation was only
accepted if present in at least two experiments. In this way 17
cross-links were identiﬁed (Table 2) and the corresponding dis-
tances were measured in the only known structure of calnexin,
the dog calnexin (PDB accession number 1JHN).
Cross-linked peptides from the contaminating ERp72 were also
observed. These conformed to the ones previous observed [20].
Discussion
Puriﬁcation of Crt from human placenta was slightly improved
compared to previous procedures by inclusion of Ca2+ in extraction
and chromatography buffers. This makes it possible to purify Crt
with only a single chromatographic step (ion exchange chromatog-
raphy), whereas a size exclusion chromatography step was usually
necessary to obtain pure Crt without addition of CaCl2. As shown in
Table 1, this reproducibly yielded about 15 mg of highly pure Crt
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ion proﬁles of major protein constituents are indicated and the locations of fractions
formed 3 times with identical results.












Fig. 6. SDS–PAGE analysis of selected fractions from Fig. 5. The gel was silver-
stained and the contents of the lanes are as follows: 1. Molecular weight standard,
2. Fr. 113, 3. Fr. 117, 4. Fr. 120, 5. Fr. 125, 6. Fr. 130, 7. Fr. 135, 8. Fr. 140, 9. Fr. 145,
10. Fr. 150.
Table 2
Cross-links observed in sCnx by cross-linking with BS3, digestion with trypsin,
analysis by LC–MS/MS and identiﬁcation by CrossWork. Only cross-linked peptides
observed in at least two out of three separate experiments are shown. Numbering is
based on the active human calnexin sequence (UniProt P27824). A few residues (70,
79 and 438) are not part of the pdb structure (1JHN) and the distances listed in
brackets are to residues ultimate ([]) or penultimate ([[]]) to the linked residue.
Fraction
number




4 67–70 17 [6.3]
4, 3 150–187 15 13.8
3, 2, 1 67–83 16 12.1
4 70–107 22 [10.9]
4 83–107 22 8.7
4 107–213 18 21.1
4 67–107 16 12.4
4 187–197 15 9.9
4, 3 98–107 15 21.7
4 107–438 14 [30.9]
4 79–107 11 [[24.7]]
4, 3, 2 69–83 23 14.6
3 187–438 14 [40.1]
3 83–213 13 21.1
3 70–83 19 [14.6]
3 93–213 14 13.4
3, 2 98–213 10 16.1
110 D.T. Olsen et al. / Protein Expression and Puriﬁcation 92 (2013) 105–111under all conditions, with and without Ca2+ present. This indicates
that human placenta Crt does not form stable complexes with
other proteins, including ERp57 and PPI. During this work, a solu-
ble Cnx was identiﬁed, isolated and characterized as a ‘‘side prod-
uct’’ of Crt puriﬁcation. The sCnx behaved very similar to Crt and
eluted as a separate peak together with mainly ERp72 just before
the Crt peak (Fig. 3). Further puriﬁcation to homogeneity of sCnx
proved somewhat difﬁcult as it behaved similar to ERp72 in many
respects. However, partial separation of the two was achieved by
hydrophobic interaction chromatography on Phenyl-Sepharose.
The yield of sCnx from a placenta was very reproducible, approxi-
mately 3 mg compared to 15 mg Crt per placenta. Thus, sCnx
amounted to approximately 20% of the Crt amount, which was
quite signiﬁcant, considering that Cnx is a membrane protein,
and would not be expected to co-purify with Crt since the extrac-
tion was carried out in the presence of protease inhibitors, and
since no signs of Crt proteolysis were seen.
Previously, a Crt form lacking the C-terminal hexapeptide has
been observed in Crt preparations also obtained after extraction
in the presence of protease inhibitor cocktails [11]. This form arose
by cleavage between Gly and Gln. Characterization of the soluble
Cnx showed that it had been cleaved between Gln 472 and Met473, thus liberating if from the ER membrane. No signs of hetero-
geneity in the cleavage site were found, neither by chromatogra-
phy nor by mass spectrometry, thus suggesting cleavage by a
rather speciﬁc protease. Cathepsin P, a member of the group of
placentally expressed cathepsins [21], has been reported to be
capable of limited processing of calreticulin from the C-terminus
[22], which obviously removes the KDEL sequon. Other placentally
expressed proteases are cathepsin L and B [21,23], metalloproteas-
es [24] and caspases [25]. Crt has been found to be a substrate for
at least one caspase [26] and the cleavage sites deﬁned by the Crt
form lacking the C-terminal hexapeptide [11] and the sCnx de-
scribed here could indicate processing by a caspase or caspase-like
enzyme. Alternatively, some kind of chemical cleavage or auto-
cleavage could have occurred.
In order to verify the structure of the soluble Cnx, three samples
were cross-linked with BS3, digested with trypsin and analysed by
mass spectrometry following previous procedures [20]. Of the 17
observed cross-links, 11 were deﬁned in the only released Cnx
structure (PDB 1JHN) and were all well within the size limits of
BS3 and two times lysine (25 Å). Four linkages were observed
to a ﬂexible loop region (residues 70–80), but the distances still
conform to the expected limits. Two linkages were observed from
residue 438 to residue 128 and 208, respectively, which are highly
unlikely based on the published structure due to a length of 30.9 Å
and 40.1 Å. Residues 128 and 208 are both located on the opposite
surface of Cnx relative to the C-terminal residue 437 of 1JHN. This
indicates that while the majority of the protein has the same con-
formation as 1JHN, the C-terminal end of sCnx may be in a different
conformation that brings residue 428 close to the opposite surface
of sCnx.
The existence of a soluble form of Cnx in substantial amounts
raises the question of a possible physiologic function of this sCnx.
Cnx and Crt can substitute for each other with regard to several
chaperone activities and appear to have overlapping substrate
speciﬁcities [8,9,27,28]. Therefore, a soluble Cnx may simply carry
out some of the functions also provided by Crt. Crt has also been
reported to function as a signalling molecule, mainly in relation
to apoptosis, where it appears on the cell surface as one of the ﬁrst
detectable molecules [29,30]. A similar function may be performed
by sCnx. Indeed, Cnx has been reported to be exposed on the sur-
face upon apoptosis [31].Acknowledgments
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